InvestorsHub Logo
Followers 4
Posts 1194
Boards Moderated 0
Alias Born 10/03/2015

Re: NY1972 post# 425

Monday, 11/21/2016 9:57:05 PM

Monday, November 21, 2016 9:57:05 PM

Post# of 977
Latest preclinical publication points to why the DLBCL pt experienced progression-free interval of 161 days @ .05 mg/kg which is only 25% of the selected dose.

you only have to bind to a smattering of the CD47 on tumor cells to produce a response

http://www.siliconinvestor.com/readmsg.aspx?msgid=30855094